ORIGINAL ARTICLE

Plasma leptin levels and cardiac sympathetic function in patients with obstructive sleep apnoea-hypopnoea syndrome

K Shimizu¹, K Chin², T Nakamura^1,2, H Masuzaki⁴, Y Ogawa⁴, R Hosokawa³, A Niimi¹, N Hattori¹, R Nohara³, S Sasayama³, K Nakao⁴, M Mishima¹, T Nakamura^1,2, M Ohi⁵

¹ Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
² Department of Physical Therapeutics, Kyoto University Hospital of Medicine, Kyoto, Japan
³ Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
⁴ Department of Clinical Science, Kyoto University Graduate School of Medicine
⁵ Department of Internal Medicine, Osaka Kaisei Hospital, Japan

Correspondence to:
Correspondence to:
Dr K Chin, Department of Physical Therapeutics, Kyoto University Hospital of Medicine, 54 Shogoin Kawahara-cho, Sakyo-Ku, 606–8507 Kyoto, Japan;
chink{at}kuhp.kyoto-u.ac.jp

Background: The control of body weight and cardiac sympathetic function in patients with obstructive sleep apnoea-hypopnoea syndrome (OSAHS) are important because both factors have significant effects on the mortality of these patients. It has recently been reported that OSAHS has a significant effect on the secretion of leptin, a hormone involved in the control of body weight and sympathetic nerve activity. In addition to the circadian rhythm of leptin secretion, the effects of one night of treatment with nasal continuous positive airway pressure (nCPAP) and the mechanism of the effects of nCPAP on nocturnal leptin secretion in patients with OSAHS has not yet been elucidated.

Methods: Blood samples were obtained at 21.00 hours, 00.00 hours, 03.00 hours, and 06.30 hours from 21 subjects with OSAHS (mean apnoea and hypopnoea index 52.4/h), with and without nCPAP treatment. Iodine-123 (I¹²³)-meta-iodobenzylguanidine (MIBG) imaging was used to evaluate myocardial sympathetic function before nCPAP treatment.

Results: Plasma leptin reached a peak level at 00:00 hours (p<0.01) in patients with OSAHS, both with and without nCPAP treatment. The first night of nCPAP treatment significantly decreased the plasma leptin levels at 03.00 hours (without nCPAP: mean (SE) 21.6 (4.7) ng/ml; with nCPAP: 19.3 (4.1) ng/ml, p<0.02) and at 06.30 hours (without nCPAP: 17.6 (3.8) ng/ml; with nCPAP: 15.2 (3.2) ng/ml, p<0.01). The magnitude of the decrease in leptin levels after nCPAP treatment was significantly correlated with cardiac sympathetic function measured before nCPAP treatment (p<0.03).

Conclusions: Patients with OSAHS undergo nocturnal increases in leptin levels in spite of interruption of sleep due to apnoea and hypopnoea, a trend seen in normal subjects. Plasma leptin levels in patients with OSAHS decreased significantly after the first night of nCPAP treatment. Enhanced cardiac sympathetic function in these patients may contribute to the leptin levels before nCPAP treatment and vice versa.

Keywords: leptin; obstructive sleep apnoea-hypopnoea syndrome; cardiac sympathetic function

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Vorona, R. D. (2009). Sleep, Sleep Disorders, and the Endocrine System. ACCP Sleep Med Brd Rev 4: 163-184 [Full Text]  
• Buyse, B., the participants of working group 2, (2007). Treatment effects of sleep apnoea: where are we now?. ERR 16: 146-168 [Abstract] [Full Text]  
• Parati, G., Lombardi, C., Narkiewicz, K. (2007). Sleep apnea: epidemiology, pathophysiology, and relation to cardiovascular risk. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R1671-R1683 [Abstract] [Full Text]  
• Kakkar, R. K., Berry, R. B. (2007). Positive Airway Pressure Treatment for Obstructive Sleep Apnea. Chest 132: 1057-1072 [Abstract] [Full Text]  
• McNicholas, W. T., Bonsignore, M. R., the Management Committee of EU COST ACTION B26, (2007). Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 29: 156-178 [Abstract] [Full Text]  
• Punjabi, N. M., Polotsky, V. Y. (2005). Disorders of glucose metabolism in sleep apnea. J. Appl. Physiol. 99: 1998-2007 [Abstract] [Full Text]  
• Spiegel, K., Knutson, K., Leproult, R., Tasali, E., Cauter, E. V. (2005). Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J. Appl. Physiol. 99: 2008-2019 [Abstract] [Full Text]  
• Sakurai, S., Nishijima, T., Takahashi, S., Yamauchi, K., Arihara, Z., Takahashi, K. (2005). Low Plasma Orexin-A Levels Were Improved by Continuous Positive Airway Pressure Treatment in Patients With Severe Obstructive Sleep Apnea-Hypopnea Syndrome. Chest 127: 731-737 [Abstract] [Full Text]  
• Barcelo, A., Barbe, F., Llompart, E., de la Pena, M., Duran-Cantolla, J., Ladaria, A., Bosch, M., Guerra, L., Agusti, A. G. N. (2005). Neuropeptide Y and Leptin in Patients with Obstructive Sleep Apnea Syndrome: Role of Obesity. Am. J. Respir. Crit. Care Med. 171: 183-187 [Abstract] [Full Text]  
• Nakamura, T., Chin, K., Hosokawa, R., Takahashi, K., Sumi, K., Ohi, M., Mishima, M. (2004). Corrected QT Dispersion and Cardiac Sympathetic Function in Patients With Obstructive Sleep Apnea-Hypopnea Syndrome. Chest 125: 2107-2114 [Abstract] [Full Text]  
• Sanner, B.M., Kollhosser, P., Buechner, N., Zidek, W., Tepel, M. (2004). Influence of treatment on leptin levels in patients with obstructive sleep apnoea. Eur Respir J 23: 601-604 [Abstract] [Full Text]  
• Saaresranta, T., Polo, O. (2003). Sleep-disordered breathing and hormones. Eur Respir J 22: 161-172 [Abstract] [Full Text]